Scotland Coronary Prevention Study

Caro J., W. Klittich, A. McGuire, and 1. Ford. 1997. The West of Scotland Coronary Prevention Study Economic Benefit Analysis of Primary Prevention with Pravastatin. British Medical Journal 315 1577-1582. 

J Shepherd, SM Cobbe, I Ford, CG Isles, AR Lorimer, PW MacFarlane, JH McKil-lop, CJ Packard. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 33 1301-1307, 1995. 

In the general population for primary prevention of CHD The West of Scotland Coronary Prevention Study (WOSCOPS) (9), Air Force/Texas coronary atherosclerosis Prevention study (AFCAPS/TexCAPS) (10), and the completed but unpublished MEGA study in Japan (A. Nakamura, presented to AHA Scientific Sessions, November 2005). 

Cross-validation in survival analysis. Statistics in Medicine 12 2305-2314 West of Scotland Coronary Prevention Group (1996). West of Scotland Coronary Prevention Study identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348 1339-1342... 

Sattar N, Gaw A, Scherbakova O, Ford I, O Reilly DSJ, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 108 414-419. 

Of particular interest are the results of the West of Scotland Coronary Prevention Study in which the relationship between the observed incidence of coronary heart disease events was compared with that predicted from an equation that incorporates cholesterol levels, smoking history, diabetes, blood pressure, and other risk factors that were known at the time (38). These results, shown in Figure 17.5, indicate that the predicted and observed event rates in patients who received placebo were similar. On the other hand, coronary event rates in pravastatin-treated patients were consistently lower than were... 

FIGURE 17.5 Comparison of observed risk of a coronary heart disease event ( ) and predicted risk (lines) for patients receiving either placebo or pravastatin over the 4.4-year duration of the West of Scotland Coronary Prevention Study. (Reproduced with permission from West of Scotland Coronary Prevention Group. Circulation 1998,97 1440-5.)... 

West of Scotland Coronary Prevention Study. Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996 348 1339. 

AECAPS/TexCAPS = Air ForceAexas Coronary Atherosclerosis Prevention Study (Downs et ah, 1998) Helsinki = The Helsinki Heart Study (Frick et al., 1 987) LRC-CPPT = The Lipid Research Clinics Coronary Primary Prevention Trial (insull et al., 1984) Oslo = The Oslo Study (Hjermann et ah, 1988) WOSCOPS = The West of Scotland Coronary Prevention Study (Shepherd et al., 1995) ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial approximately 13-15% of patients had a history of coronary heart disease (CHD) events are CHD events only WHI = Women s Health initiative RRR = relative risk reduction ARR = absolute risk reduction NNT = number needed to treat NA = not available CEE = conjugated equine estrogen MPA = medroxyprogesterone acetate CARDS = Collaborative Atorvastatin Diabetes Study (presented at the 2004 American Diabetes Association meeting). 

VA-HIT Veterans Administration High-Density Lipoprotein Cholesterol (HDL-C) Intervention Trial VCAM-1 Vascular cell adhesion molecule VEGF Vascular endothelial growth factor VLDL Very low-density lipoproteins WHI Women s Health Initiative WHO World Health Organization WOSCOPS West of Scotland Coronary Prevention Study... 

Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study Economic benefit analysis of primary prevention with pravastatin. BrMedJ 1997 315 1577-1582. 

Primary prevention trials such as Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) (i i, 72), West of Scotland Coronary Prevention Study Group (WOSCOPS) (13,14), and the... 

---